We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Adds Plasma Fibrinogen as Biomarker in COPD Trials
FDA Adds Plasma Fibrinogen as Biomarker in COPD Trials
The FDA is adding plasma fibrinogen as a prognostic biomarker for patient selection in clinical trials involving chronic obstructive pulmonary disease and a high risk of death.